0IIM logo

Esperion Therapeutics LSE:0IIM Stock Report

Last Price

US$1.51

Market Cap

US$296.8m

7D

-5.8%

1Y

-29.1%

Updated

16 Mar, 2025

Data

Company Financials +

Esperion Therapeutics, Inc.

LSE:0IIM Stock Report

Market Cap: US$296.8m

0IIM Stock Overview

A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. More details

0IIM fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Esperion Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Esperion Therapeutics
Historical stock prices
Current Share PriceUS$1.51
52 Week HighUS$3.86
52 Week LowUS$1.48
Beta1.04
1 Month Change-18.49%
3 Month Change-36.34%
1 Year Change-29.08%
3 Year Change-70.53%
5 Year Changen/a
Change since IPO-97.98%

Recent News & Updates

Recent updates

Shareholder Returns

0IIMGB PharmaceuticalsGB Market
7D-5.8%-1.2%-0.5%
1Y-29.1%10.2%8.5%

Return vs Industry: 0IIM underperformed the UK Pharmaceuticals industry which returned 10.2% over the past year.

Return vs Market: 0IIM underperformed the UK Market which returned 8.5% over the past year.

Price Volatility

Is 0IIM's price volatile compared to industry and market?
0IIM volatility
0IIM Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement8.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.1%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0IIM's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0IIM's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2008304Sheldon Koenigwww.esperion.com

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.

Esperion Therapeutics, Inc. Fundamentals Summary

How do Esperion Therapeutics's earnings and revenue compare to its market cap?
0IIM fundamental statistics
Market capUS$296.77m
Earnings (TTM)-US$51.74m
Revenue (TTM)US$332.31m

0.9x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0IIM income statement (TTM)
RevenueUS$332.31m
Cost of RevenueUS$114.84m
Gross ProfitUS$217.48m
Other ExpensesUS$269.22m
Earnings-US$51.74m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin65.44%
Net Profit Margin-15.57%
Debt/Equity Ratio-150.7%

How did 0IIM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 12:32
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Esperion Therapeutics, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Thomas ShraderBTIG
Kristen KluskaCantor Fitzgerald & Co.